Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients.
106 HIV-positive patients with 129 episodes of oropharyngeal Candida infection were treated with fluconazole (50-300 mg/d). Treatment lasted from 4 to 23 days. The majority of patients were in more advanced stages of HIV infection (82% AIDS cases). Therapy with fluconazole led to complete healing or improvement of clinical symptoms in 93% of all treatment courses. However, according to cultural findings, an elimination or recession of pathogens was achieved in only 70% of cases. Cultural monitoring showed a slow reduction of pathogens, as opposed to a fairly rapid clinical improvement. Candida albicans was the most frequently isolated Candida species (n = 128); the most selected Candida species during treatment were C. glabrata, C. krusei, and C. inconspicua. It is remarkable that C. glabrata, a low-grade pathogen, caused enanthema in 2 patients and a typical oral thrush in 1 patient. Fluconazole was well-tolerated, and apart from mild gastro-intestinal symptoms in 1 patient, no severe side effects were observed.
Just-Nübling
G
G
Zentrum für Innere Medizin/Infektiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany.
Gentschew
G
G
Döhle
M
M
Böttinger
C
C
Helm
E B
EB
Stille
W
W
D000328:Adult; D001772:Blood Cell Count / Q000187:drug effects; D002175:Candida / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000209:etiology; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use*; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008875:Middle Aged
D015725:Fluconazole